All In Biotech

Drug Trial Radar · NCT06677255

A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatment

A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of VUM02 Injection in the Treatment of Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 149 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

149

Planned (sponsor's estimate)

Start

Jan 2025

Primary completion

Dec 2026

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Nov 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 14 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is a phase I/II clinical study to evaluate the safety, tolerability and preliminary efficacy of VUM02 Injection in patients with acute graft-versus-host disease (aGvHD) who have failed systemic steroid therapy. VUM02 Injection (human umbilical cord-derived mesenchymal stromal /stem cells, hUC-MSC) is an off-the-shelf allogeneic cell therapy product comprising culture-expanded mesenchymal stromal /stem cells derived from the human umbilical cord tissue. The product is cryopreserved with the cell concentration of 5 x 10\^6 cells/mL. Patients with grade II to IV aGvHD who have failed systemic steroid therapy (i.e. patients with steroid-refractory aGvHD (SR-aGvHD)), will be recruited into this study. This study consists of two phases, a dose-escalation phase (phase I) and a dose-expansion phase (phase II).

Conditions

  • Steroid-refractory Acute Graft-versus-host Disease

Interventions

  • VUM02 Injection (UC-MSCs)+BATDrug

    The dose-escalation phase (phase I): Single dose escalation Phase 1a study: 3 dose levels of a single IV infusion; Multiple dose escalation Phase 1b study: 3 dose levels of twice weekly for 4 consecutive week. The dose-expansion phase (phase II): -Two dose groups will be selected by the investigator and the sponsor based on the results of the Phase 1b study, twice a week for 4 consecutive weeks for a total of 8 doses.

  • The control group with Best Available Therapy (BAT)Other

    According to BAT scheme, the drug administration is determined by PI according to the condition of the patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Dose-limiting toxicity (DLT) events (in Phase Ia and Ib )Time frame: 14 days, 28 days after the last dosing
  2. Overall response rate (ORR) at day 28 post initiation of therapy (in Phase II)Time frame: 28 days after the first dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.